Abiopharma

🔍 Sandler Laura Lee (Executive)

Company: Oruka Therapeutics, Inc. (ORKA)

Report Date: 2026-09-01

Detailed Transactions and Holdings:

• Acquired 5,000 shares of Common Stock at $7.8 per share (Direct)
  Date: 2026-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 241,384.00 | transaction_form_type: 4
• Sold 1,000 shares of Common Stock at $91.0476 per share (Direct)
  Date: 2026-09-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 240,384.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 4,000 shares of Common Stock at $92.0134 per share (Direct)
  Date: 2026-09-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 236,384.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 5,000 shares of Employee Warrant (right to buy) at $7.8 per share (Derivative)
  Date: 2026-09-01 | Code: M | Expires: 2034-07-14 | equity_swap_involved: 0 | shares_owned_after: 74,996.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.51 to $91.49, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.60 to $92.59, inclusive.
• F4: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.